Mellgen (Shenzhen) Biotechnology Co., Ltd.
Address: 3rd Floor, Building A23, Life Science Industrial Park, Kuichong Sub-district, Dapeng New District, Shenzhen, Guangdong, China

Transdermal Recombinant Protein/Peptides
Humanized recombinant fibronectin overcoming biomacromolecular transdermal barriers, equipped with patented cell-penetrating peptide technology to deeply anchor integrin receptors, achieving rapid barrier emergency rescue and ECM network reconstruction.
INCI Name: Aqua, Recombinant Fibronectin, Butylene Glycol, 1,2-Hexanediol
Appearance & Solubility: Clear colorless liquid, odorless, Easily miscible with aqueous phase and hydrogels
Recommended Dosage: 1.0% - 5.0% (Recommended 2.0% - 3.0%)
Hotline: 136-9197-8530
Humanized recombinant fibronectin overcoming biomacromolecular transdermal barriers, equipped with patented cell-penetrating peptide technology to deeply anchor integrin receptors, achieving rapid barrier emergency rescue and ECM network reconstruction.
Scientific Illustration Transdermal Fibronectin - Mechanism & Scientific Evidence
Comprehensive Technical, Quality Specification, and Regulatory Dossier for R&D Formulators, Procurement, and Product Managers
Regulatory & Professional Compliance Statement:
1. The raw material characteristics and experimental data (including cytological studies, mechanism diagrams, and literature citations) presented on this webpage are intended exclusively for technical discussion and formulation R&D reference by cosmetic brand formulators, R&D engineers, product planners, and academic research institutions. They do not constitute finished consumer cosmetic efficacy claims or commercial warranties.
2. Pursuant to the Regulations on the Supervision and Administration of Cosmetics, Standards for Cosmetic Efficacy Claim Evaluation, and relevant global cosmetic regulatory frameworks, cosmetic brand enterprises utilizing this raw material shall be solely responsible for the safety, stability, and efficacy claims of their finished consumer products, and shall independently complete efficacy evaluations and regulatory filings/registrations with the competent health authorities prior to commercial launch. Conclusions from in-vitro or cellular studies shall not be directly extrapolated as consumer claims.
3. Mellgen Biotech assumes no joint or indirect liability for any claims or regulatory non-compliance arising from improper customer formulation, unauthorized off-label claims, or unverified applications.


